These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33868476)

  • 1. Recombinant protein TRAIL-Mu3 enhances the antitumor effects in pancreatic cancer cells by strengthening the apoptotic signaling pathway.
    Huang M; Yi C; Huang XZ; Yan J; Wei LJ; Tang WJ; Chen SC; Huang Y
    Oncol Lett; 2021 Jun; 21(6):438. PubMed ID: 33868476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
    Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antitumor Activity of TRAIL-Mu3 Protein
    Yang T; Zhu AJ; Wang JS; Jin Z
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):304-311. PubMed ID: 32543134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRAIL induces apoptosis but not necroptosis in colorectal and pancreatic cancer cells preferentially via the TRAIL-R2/DR5 receptor.
    Nahacka Z; Svadlenka J; Peterka M; Ksandrova M; Benesova S; Neuzil J; Andera L
    Biochim Biophys Acta Mol Cell Res; 2018 Mar; 1865(3):522-531. PubMed ID: 29278689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy of pancreatic cancer with green fluorescent protein and tumor necrosis factor-related apoptosis-inducing ligand fusion gene expression driven by a human telomerase reverse transcriptase promoter.
    Katz MH; Spivack DE; Takimoto S; Fang B; Burton DW; Moossa AR; Hoffman RM; Bouvet M
    Ann Surg Oncol; 2003 Aug; 10(7):762-72. PubMed ID: 12900367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
    Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
    J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
    Yu R; Albarenque SM; Cool RH; Quax WJ; Mohr A; Zwacka RM
    Cancer Biol Ther; 2014; 15(12):1658-66. PubMed ID: 25482930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in established and primary glioma cell lines.
    Jaganathan J; Petit JH; Lazio BE; Singh SK; Chin LS
    Neurosurg Focus; 2002 Sep; 13(3):ecp1. PubMed ID: 15844877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
    Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells.
    Tanaka R; Tomosugi M; Horinaka M; Sowa Y; Sakai T
    PLoS One; 2015; 10(5):e0125779. PubMed ID: 25955843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer.
    Ozawa F; Friess H; Kleeff J; Xu ZW; Zimmermann A; Sheikh MS; Büchler MW
    Cancer Lett; 2001 Feb; 163(1):71-81. PubMed ID: 11163110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alkyllysophospholipid edelfosine enhances TRAIL-mediated apoptosis in gastric cancer cells through death receptor 5 and the mitochondrial pathway.
    Lim SC; Parajuli KR; Han SI
    Tumour Biol; 2016 May; 37(5):6205-16. PubMed ID: 26615420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIF-2α dictates the susceptibility of pancreatic cancer cells to TRAIL by regulating survivin expression.
    Harashima N; Takenaga K; Akimoto M; Harada M
    Oncotarget; 2017 Jun; 8(26):42887-42900. PubMed ID: 28476028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HSP70 and autophagy inhibitor pifithrin-μ enhances the antitumor effects of TRAIL on human pancreatic cancer.
    Monma H; Harashima N; Inao T; Okano S; Tajima Y; Harada M
    Mol Cancer Ther; 2013 Apr; 12(4):341-51. PubMed ID: 23371857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor necrosis factor-related apoptosis-inducing ligand inhibits the growth and aggressiveness of colon carcinoma via the exogenous apoptosis signaling pathway.
    Gong H; Cheng W; Wang Y
    Exp Ther Med; 2019 Jan; 17(1):41-50. PubMed ID: 30651763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Khanbolooki S; Nawrocki ST; Arumugam T; Andtbacka R; Pino MS; Kurzrock R; Logsdon CD; Abbruzzese JL; McConkey DJ
    Mol Cancer Ther; 2006 Sep; 5(9):2251-60. PubMed ID: 16985059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
    Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.